LGM
FATE icon

Logos Global Management’s Fate Therapeutics FATE Stock Holding History

Logos Global Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-94,000
Closed -$5.5M – 54
2021
Q4 		$5.5M Buy
+94,000
New +$5.33M 0.57% 39
2020
Q2 		– Sell
-193,144
Closed -$4.29M – 53
2020
Q1 		$4.29M Buy
+193,144
New +$4.88M 1.63% 25

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Logos Global Management's FATE Position: Q1 2022 in Review

Logos Global Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 94,000 shares — an estimated $5.5M sold.

Logos Global Management first reported a position in FATE in Q1 2020 and held it in 2 quarters. The position peaked at $5.5M in Q4 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Logos Global Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 94,000 Fate Therapeutics shares in Q1 2022, an estimated $5.5M.
  • Logos Global Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 2 quarters.
  • Logos Global Management's Fate Therapeutics position peaked at $5.5M in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.